<DOC>
	<DOCNO>NCT01436110</DOCNO>
	<brief_summary>A randomised , double-blind , double-dummy , placebo control multi-centre study evaluate efficacy safety fluticasone furoate inhalation powder fluticasone propionate inhalation powder treatment asthma adult adolescent currently treat inhaled corticosteroid</brief_summary>
	<brief_title>Clinical Study Evaluating Safety Efficacy Fluticasone Furoate Fluticasone Propionate People With Asthma</brief_title>
	<detailed_description>This multi-centre , randomise , placebo active control ( rescue medication ) , double-blind , double-dummy , parallel-group study . Subjects meet inclusion criterion none exclusion criterion Visit 1 ( Screening Visit ) enter two week Run-in Period . Subjects fail screen eligible re-screening . During run-in double-blind treatment period subject maintain electronic daily diary record morning even peak expiratory flow ( PEF ) , asthma symptom score rescue albuterol/salbutamol use . At Visit 2 ( end run-in/Randomisation Visit ) , subject meet eligibility criterion randomise receive treatment either fluticasone furoate 50 mcg daily , fluticasone propionate 100 mcg twice daily placebo . In addition subject supply albuterol/salbutamol inhalation aerosol use require treat symptom . Subjects attend 6 on-treatment visit Visits 3 , 4 , 5 , 6 , 7 8 ( Weeks 2 , 4 , 8 , 12 , 18 24 respectively ) . Subjects receive treatment 24 week . A follow-up contact perform 1-week completing study medication ( Visit 9 ) . Subjects participate study maximum 27 week ( include screening , treatment follow-up contact ) .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Signed informed consent Outpatient least 12 year age diagnosis asthma least 12 week prior first visit Both gender ; female child bear potential must willing use appropriate contraception study Prebronchodilator FEV1 least 60 % predict FEV1 reversibility least 12 % 200ml Current asthma therapy include noncorticosteroid controller and/or short act betaagonist History lifethreatening asthma exacerbation past 10 year Asthma exacerbation require oral corticosteroid within past 3 month overnight hospital stay within past 6 month Current recent respiratory infection current oral candida infection Presence significant respiratory disease medical condition uncontrolled could affect subject safety study outcome Known suspect allergy study medication material Taking another investigational medication prohibit medication study Current smoker former smoker significant tobacco exposure Previous treatment fluticasone furoate phase II III study Children Care</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>